Upadacitinib for moderate to severe atopic dermatitis
| Autor: | Francisco Navarro-Triviño, Sara Alcantara-Luna, Javier Domínguez-Cruz, Manuel Galán-Gutiérrez, Ricardo Ruiz-Villaverde, José-Juan Pereyra-Rodriguez, José-Carlos Armario-Hita |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | Immunotherapy. |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2023-0037 |
| Popis: | Atopic dermatitis is an inflammatory skin disease, the prevalence of which has increased in the last decade. It affects all age groups, with adult involvement being a major focus of interest in recent years. The unmet needs of the disease, such as pruritus, sleep quality impairment and eczematous skin lesions, have undergone a therapeutic revolution following the commercialization of drugs such as JAK inhibitors. Upadacitinib, a selective JAK1 inhibitor, has been positioned by both clinical trial results and those observed in clinical practice as the fastest and most effective drug in reducing both pruritus and Eczema Area and Severity Index and validated Investigator Global Assessment. Although the safety profile may be initially alarming, it is advisable to update the actual data in this regard for proper management. New perspectives for upadacitinib in nonatopic comorbidities such as psoriasis and alopecia areata are beginning to be described, and interest in learning more about its peculiarities is growing. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|